GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

inclisiran   Click here for help

GtoPdb Ligand ID: 13624

Synonyms: ALN-60212 | ALN-PCSsc | Leqvio®
Approved drug
inclisiran is an approved drug (EMA (2020), FDA & UK MHRA (2021))
Compound class: Nucleic acid
Comment: Inclisiran is a small interfering RNA (siRNA) class drug that targets the proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA, to reduce production of the PCSK9 protein [6].
Individual nucleotides are chemically modified to improve stability, and the structure has terminal GalNac (sugar) conjugation for hepatic targeted delivery. We have been unable to locate a full chemical SMILES for the drug, or its HELM notation.
Classification Click here for help
Compound class Nucleic acid
Compound subclass siRNA
Target PCSK9 mRNA
Approved drug? Yes. UK MHRA (2021)  |  EU EMA (2020)  |  US FDA (2021)
International Nonproprietary Names Click here for help
INN number INN
10268 inclisiran
Synonyms Click here for help
ALN-60212 | ALN-PCSsc | Leqvio®
Database Links Click here for help
CAS Registry No. 1639324-58-5 (source: WHO INN record)
ChEMBL Ligand CHEMBL5095052
DrugBank Ligand DB14901
GtoPdb PubChem SID 504705443
Search PubMed clinical trials inclisiran
Search PubMed titles inclisiran
Search PubMed titles/abstracts inclisiran